Paris, France, April 8, 2020, 8.00 pm CET – GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2019 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.20-0271.
The universal registration document notably includes:
- the 2019 annual financial report;
- the management report;
- the report on corporate governance; and
- the description of the share buyback program.
This universal registration document may be consulted on the Company’s website (www.gensight-biologics.com), “Investors” section, and on the AMF’s website (www.amf-france.org).
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010), is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
GenSight BiologicsChief Financial OfficerThomas Gidoin+33 (0)1 76 21 72 20
Rooney PartnersMedia RelationsMarion Janic+1-212-223-4017
LifeSci AdvisorsInvestor RelationsGuillaume van Renterghem+33 (0)6 69 99 37 83
James PalmerRetail Investors+33 7 60 92 77 74